Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)

Cancers, Journal Year: 2024, Volume and Issue: 16(10), P. 1806 - 1806

Published: May 9, 2024

Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small-Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies on a variety factors which may allow identification novel biomarkers. Presently, biomarkers are under investigation, including PD1/PDL1 axis, tumor mutational burden, and microbiota. latter is made bacteria other microorganisms hosted in our body. gut microbiota most represented has been involved different physiological pathological events, cancer. In light, it appears that conditions modifying can influence cancer, its treatment, treatment-related toxicities. aim review to analyze influencing and, therefore, affecting response immunotherapy, iRAEs, their management NSCLC patients. investigation landscape these biological events insights into optimal

Language: Английский

---

The multipotential effect of microbiome in lung cancer development and progression

International review of cell and molecular biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Exploring the prognostic role of microbial and genetic markers in lung squamous cell carcinoma

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 6, 2025

Abstract Despite advances in diagnostic and therapeutic strategies, the prognosis of lung squamous cell carcinoma (LUSC) patients remains poor, potential microbiome-based prognostic biomarkers targets largely unexplored. LUSC patient data from The Cancer Genome Atlas (TCGA), including microbial genus level abundance RNA sequencing (RNA-Seq) data, were used as a training dataset. Two other independent datasets GSE19188 GSE157009 serve validation datasets. A risk score (RS) model was constructed by univariate Cox regression analysis combined with least absolute contraction selection operator (LASSO) regression. 18 genera found to be significantly associated RFS patients. signature built these genera, exhibited robust predictive accuracy both Furthermore, hub mRNA between high- low-risk groups selected XGBOOST intersect mRNAs screened analysis, finally identifying four prognosis. This study reveals complex interplay microbiome genetic biomarkers, identifies specific microbial-based LUSC. These findings provide basis for future studies aimed elucidate mechanisms underlying associations guiding treatment decisions improving outcomes.

Language: Английский

---

Prioritizing gut microbial SNPs linked to immunotherapy outcomes in NSCLC patients by integrative bioinformatics analysis

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 17, 2025

The human gut microbiome has emerged as a potential modulator of treatment efficacy for different cancers, including non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor (ICI) therapy. In this study, we investigated the association microbial variations with response against ICIs by analyzing metagenomes NSCLC patients. Strain identification from publicly available 87 patients, treated nivolumab and collected at three timepoints (T0, T1, T2), was performed using StrainPhlAn3. Variant calling annotations were Snippy associations between genes genomic responses evaluated MaAsLin2. Supervised machine learning models developed to prioritize single nucleotide polymorphisms (SNPs) predictive response. Structural bioinformatics approaches employed MUpro, I-Mutant 2.0, CASTp PyMOL access functional impact prioritized SNPs on protein stability active site interactions. Our findings revealed presence strains several species (e.g., Lachnospira eligens) exclusively in Responders (R) or Non-responders (NR) Parabacteroides distasonis). identified R NR highlighted ftsA, lpdA, nadB) that significantly associated status Among models, Logistic Regression best (accuracy > 90% AUC ROC 95%) prioritizing could distinguish T0. These included Ala168Val (lpdA) Phocaeicola dorei Tyr233His (lpdA), Leu330Ser His233Arg (obgE) distasonis. Lastly, structural analyses these variants objE lpdA their involvement substrate binding an overall reduction stability. This suggests might likely disrupt interactions compromise stability, thereby impairing normal functionality. integration metagenomics, learning, provides robust framework understanding response, paving way personalized therapies future. emphasize clinical implications microbiome-based biomarkers guiding patient-specific strategies improving immunotherapy outcomes.

Language: Английский

---

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)

Published: March 15, 2024

Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies to a variety factors which may allow identification novel biomarkers. Presently, biomarkers are under investigation, including PD1/PDL1 axis, tumor mutational burden, and Microbiota. This latter is made bacteria other microorganisms hosted in our body. gut microbiota most represented has been involved different physiological pathological events, cancer. In light, it appears that conditions modifying can influence cancer, its treatment, treatment-related toxicities. aim review analyze influencing and, therefore, affecting response immunotherapy, iRAEs their management NSCLC patients. investigation landscape these biological events insights optimal

Language: Английский

---

Microbiome-Mucosal Immunity Nexus: Driving Forces in Respiratory Disease Progression

The Journal of Microbiology, Journal Year: 2024, Volume and Issue: 62(9), P. 709 - 725

Published: Sept. 1, 2024

Language: Английский

---